A Randomized, Phase III, Double-Blind, Placebo-Controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy.

Trial Profile

A Randomized, Phase III, Double-Blind, Placebo-Controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Memantine (Primary)
  • Indications Cognition disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 29 Jun 2010 New source identified and integrated (Moores UCSD Cancer Center, 6858).
    • 24 Nov 2009 Additional lead trial investigator (Harold K) identified as reported by Barbara Ann Karmanos Cancer Institute record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top